April 2017 Vol 8, No 4

The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib demonstrated encouraging activity in patients with advanced neuroendocrine tumors (NETs), including patients previously treated with sunitinib or everolimus, a preliminary clinical study showed.
Constant exposure to patient distress and trauma can take a toll on oncology workers, and it often leads to a phenomenon called secondary traumatic stress, or “compassion fatigue,” according to Charles Figley, PhD, Paul Henry Kurzweg Chair in Disaster Mental Health and Director of the Traumatology Institute at Tulane University in New Orleans, LA.
Innovation takes time, especially when it comes to cancer research. Unfortunately, delays in the adoption of novel oncology treatments can have a significant effect on patient health.
The FDA’s new personalized medicine approvals and expanded indications reflect the extraordinary pace of scientific innovation in the field.
Page 2 of 2
Results 11 - 14 of 14

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country